In Phase C, individuals will get ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until illness progression or the participants are unable to tolerate the study drugs. Probable new methods for the diagnosis and treatment of AML. (A) The https://emilianotfpao.tinyblogging.com/considerations-to-know-about-is-abbv-744-effective-for-hematologic-cancers-75758365